Findings show at-home self-administered ofatumumab provides higher satisfaction in patients with multiple sclerosis, suggesting better therapy choices.
Subcutaneous ofatumumab treatment, a therapy self-administered at home, was associated with more favorable experiences compared to other high-efficacy therapies, highlighting the importance of shared decision making and organizational and logistical factors when selecting therapies for multiple sclerosis.
No takes yet. Share an insight, caveat, or question.
Pastore et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: